Shield Therapeutics (LON:STX) Stock Price Down 9.4% - Time to Sell?

Key Points

• Shield Therapeutics' stock price dropped by 9.4% on Thursday, trading as low as GBX 6.26 ($0.08) compared to its previous close of GBX 6.95 ($0.09).
• A significant trading volume increase of 183% was observed, with 7,024,918 shares changing hands during the session.
• The company specializes in delivering Accrufer®/Feraccru®, a product aimed at addressing iron deficiency, which has been launched in the U.S.

Shield Therapeutics plc (LON:STX - )'s share price fell 9.4% on Thursday . The stock traded as low as GBX 6.26 ($0.08) and last traded at GBX 6.30 ($0.08). 7,024,918 shares changed hands during trading, an increase of 183% from the average session volume of 2,479,952 shares. The stock had previously closed at GBX 6.95 ($0.09).

Shield Therapeutics Trading Up 17.5%

The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The stock's 50 day moving average price is GBX 4.77 and its 200-day moving average price is GBX 3.45. The stock has a market capitalization of £77.09 million, a P/E ratio of -246.67 and a beta of 1.42.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.